© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
The decrease is largely due to improved lung cancer treatment, but the impact of COVID-19 is not yet known.
November is Lung Cancer Awareness Month.
The premier platform not only for the presentation of new science, but also for unique networking opportunities.
In recent years, deaths from non-small cell lung cancer (NSCLC) have decreased even faster than the decrease in NSCLC incidence.
Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.
A study out of China found cancer patients had a higher coronavirus risk, possibly because of hospital visits.
ASCO and Friends of Cancer Research proposed new eligibility guidelines in 2017.
Researchers believe specially designed cancer care programs could prevent Black patients from being lost to care.
Blacks have higher rates of positive screens and lung cancer diagnosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
